308 related articles for article (PubMed ID: 32619305)
1. Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it?
Vaubel R; Zschernack V; Tran QT; Jenkins S; Caron A; Milosevic D; Smadbeck J; Vasmatzis G; Kandels D; Gnekow A; Kramm C; Jenkins R; Kipp BR; Rodriguez FJ; Orr BA; Pietsch T; Giannini C
Brain Pathol; 2021 Jan; 31(1):20-32. PubMed ID: 32619305
[TBL] [Abstract][Full Text] [Related]
2. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.
Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Bastian BC; Grenert JP; Kline CN; Mueller S; Banerjee A; Nicolaides T; Gupta N; Berger MS; Lee HS; Pekmezci M; Tihan T; Bollen AW; Perry A; Shieh JTC; Solomon DA
Brain Pathol; 2019 Jan; 29(1):85-96. PubMed ID: 30051528
[TBL] [Abstract][Full Text] [Related]
3. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
[TBL] [Abstract][Full Text] [Related]
4. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.
Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J
World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
[TBL] [Abstract][Full Text] [Related]
6. Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival.
Ebrahimi A; Korshunov A; Reifenberger G; Capper D; Felsberg J; Trisolini E; Pollo B; Calatozzolo C; Prinz M; Staszewski O; Schweizer L; Schittenhelm J; Harter PN; Paulus W; Thomas C; Kohlhof-Meinecke P; Seiz-Rosenhagen M; Milde T; Casalini BM; Suwala A; Wefers AK; Reinhardt A; Sievers P; Kramm CM; Etminam N; Unterberg A; Wick W; Herold-Mende C; Sturm D; Pfister SM; Sill M; Jones DTW; Schrimpf D; Reuss DE; Aldape K; Abdullaev Z; Sahm F; von Deimling A; Stichel D
Acta Neuropathol Commun; 2022 Jan; 10(1):5. PubMed ID: 35012690
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.
Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y
Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523
[TBL] [Abstract][Full Text] [Related]
8. Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma.
Lucas CG; Davidson CJ; Alashari M; Putnam AR; Whipple NS; Bruggers CS; Mendez JS; Cheshier SH; Walker JB; Ramani B; Cadwell CR; Sullivan DV; Lu R; Mirchia K; Van Ziffle J; Devine P; Goldschmidt E; Hervey-Jumper SL; Gupta N; Oberheim Bush NA; Raleigh DR; Bollen A; Tihan T; Pekmezci M; Solomon DA; Phillips JJ; Perry A
J Neuropathol Exp Neurol; 2022 Jul; 81(8):650-657. PubMed ID: 35703914
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
[TBL] [Abstract][Full Text] [Related]
10. Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.
Ida CM; Rodriguez FJ; Burger PC; Caron AA; Jenkins SM; Spears GM; Aranguren DL; Lachance DH; Giannini C
Brain Pathol; 2015 Sep; 25(5):575-86. PubMed ID: 25318587
[TBL] [Abstract][Full Text] [Related]
11. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations.
Murakami C; Yoshida Y; Yamazaki T; Yamazaki A; Nakata S; Hokama Y; Ishiuchi S; Akimoto J; Shishido-Hara Y; Yoshimoto Y; Matsumura N; Nobusawa S; Ikota H; Yokoo H
Brain Tumor Pathol; 2019 Jul; 36(3):103-111. PubMed ID: 30972500
[TBL] [Abstract][Full Text] [Related]
13. Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma.
Zhang H; Ma XJ; Xiang XP; Wang QY; Tang JL; Yu XY; Xu JH
Curr Oncol; 2023 Feb; 30(2):2405-2416. PubMed ID: 36826144
[TBL] [Abstract][Full Text] [Related]
14. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
[TBL] [Abstract][Full Text] [Related]
15. Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma.
Marucci G; Morandi L
J Neurooncol; 2011 Nov; 105(2):397-400. PubMed ID: 21626073
[TBL] [Abstract][Full Text] [Related]
16. Molecular features of pleomorphic xanthoastrocytoma.
Zou H; Duan Y; Wei D; Zhang Y; Dai J; Li J; Li X; Zhou J; Liu Z; Jin Z; Zhang Z; Yu Y; Hu Z
Hum Pathol; 2019 Apr; 86():38-48. PubMed ID: 30496796
[TBL] [Abstract][Full Text] [Related]
17. Acquired ATRX Loss and ALT Phenotype Through Tumor Recurrences in a Case of Pleomorphic Xanthoastrocytoma Suggest Their Possible Roles in Tumor Progression.
Dal Col P; Poncet D; Rivoirard R; Vassal F; Bernichon E; Boutet C; Péoc'h M; Forest F
J Neuropathol Exp Neurol; 2020 Sep; 79(9):1011-1014. PubMed ID: 32770176
[TBL] [Abstract][Full Text] [Related]
18. Role of a Promoter Mutation in TERT in Malignant Transformation of Pleomorphic Xanthoastrocytoma.
Hosono J; Nitta M; Masui K; Maruyama T; Komori T; Yokoo H; Saito T; Muragaki Y; Kawamata T
World Neurosurg; 2019 Jun; 126():624-630. PubMed ID: 30599247
[TBL] [Abstract][Full Text] [Related]
19. MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.
Lohkamp LN; Schinz M; Gehlhaar C; Guse K; Thomale UW; Vajkoczy P; Heppner FL; Koch A
PLoS One; 2016; 11(6):e0156422. PubMed ID: 27253461
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation alterations in grade II- and anaplastic pleomorphic xanthoastrocytoma.
Martínez R; Carmona FJ; Vizoso M; Rohde V; Kirsch M; Schackert G; Ropero S; Paulus W; Barrantes A; Gomez A; Esteller M
BMC Cancer; 2014 Mar; 14():213. PubMed ID: 24650279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
